Health Condition 1: C749- Malignant neoplasm of unspecifiedpart of adrenal gland
Conditions
Interventions
None listed
Sponsors
Vikramjit S Kanwar
Eligibility
Inclusion criteria
Inclusion criteria: 5.1 Diagnosisâ?¨All newly diagnosed patients with suspected neuroblastoma (NB), or ganglioneuroblastoma seen at participating InPOG institutions are eligible for this study. 5.2. Patients may have received emergent chemotherapy. However documentation of such exposure is needed as excessive exposure may yield samples that have inadequate tumor to analyze. 5.3 Specimens required for eligibility:â?¨It is mandatory that an effort be made to submit a neuroblastoma tissue slides of sufficient quality and quantity for genomic analysis. For patients with stage 4 disease confirmed on marrow histopathology and urine catecholamine testing, tissue biopsy is not required for registration but marrow biopsy specimen slides or aspirate sample should be sent. Similarly for low risk neuroblastoma patients followed with imaging tissue biopsy may not be available, however should they undergo a biopsy or resection at a later date tumor needs to be submitted for testing at that time. 5.4 All patients and/or their parents or legal guardians must sign a written informed consent. â?¨ 5.5 All institutional ethics requirements must be met. â?¨
Exclusion criteria
Exclusion criteria: 1. Patients who are not diagnosed with neuroblastoma.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1) Overall survival of neuroblastoma patients 2) Correlation with initial stage, treatment administered, and biologic risk factors.Timepoint: Samples and patient registration to be submitted Staging and biology assessed at time of initial diagnosis, patient outcome will be assessed 3 years from patient registration | — |
Secondary
| Measure | Time frame |
|---|---|
| To follow all patients for a period of 5 years to gain a better understanding of survival. Timepoint: Follow up to complete 2 years after last patient accrued | — |
Countries
India
Contacts
Public ContactVikramjit S Kanwar
Division Chief Pediatric Hematology-Oncology CIMS Hospital
Outcome results
None listed